The document discusses leveraging private-public partnerships (PPPs) in COVID-19 pandemic response. It provides context on global vaccine trends pre-COVID, then discusses the major impacts of the pandemic on clinical development, trials, and manufacturing. It highlights the roles of developing country vaccine manufacturers and IVI in responding through PPPs. IVI in particular has built partnerships across regions and leveraged over $30 million to develop affordable vaccines for cholera, typhoid and other diseases.
Global Vaccines Market 2020 By Technology [Conjugate vaccines, Inactivated and subunit vaccines, Live attenuated vaccines, Recombinant vaccines, Toxoid vaccines and others],By Type [Monovalent vaccines, Multivalent vaccines and others], By Patient Type[Pediatric patients, Adult patients and others], By Disease[Cancer, Dengue, DTP, Hepatitis, Human Papilloma Virus, Influenza, Meningococcal Disease, Pneumococcal disease, Polio, Rotavirus and others]: Global Forecast to 2026 and COVID-19 Impact Outlook
Global Vaccines Market is valued at USD 45.9 Billion in 2019 and expected to reach USD 91.9 Billion by 2026 with the CAGR of 10.44 % over the forecast period.
Research Dive has recently added a new report on Human Papillomavirus Vaccine Market Size Share which provides a succinct analysis of the market size, revenue forecast, and the regional landscape of Human Papillomavirus Vaccine Market Size Share
This document provides a summary of key developments from the Gavi CEO Board Update meeting on June 24-25, 2020. It discusses the global impact of the COVID-19 pandemic, the success of Gavi's replenishment and vaccine summit, Gavi's role in the COVID-19 response including efforts to ensure equitable access to vaccines, and priorities around demand generation, communities, gender and digital engagement. It also provides updates on Gavi's 2019 progress and the conclusion of the pneumococcal AMC pilot.
GLOBAL VACCINATION: HOW THE EVOLVING HEALTHCARE INFRASTRUCTURE IS SUPPORTING ...Anayasharma10
COVID-19 (coronavirus) vaccines have started becoming accessible in most countries and are probably a severe product in fighting the pandemic in 2021. Several vaccines are already in the development trails or phase three trials that have reported promising data in the initial phase, with some receiving authorization for use.
The document provides an overview of the current Canadian vaccine environment, including:
1) The global and Canadian vaccine markets, which are growing significantly but still represent a small portion of pharmaceutical markets.
2) The complex process required for introducing new vaccines, which involves regulatory approval, funding, recommendations, and infrastructure.
3) The key players in Canada's vaccine system, including manufacturers, government agencies, medical societies, and others.
4) Recommendations to improve Canada's vaccine system by recognizing its value, encouraging investment, streamlining processes, and ensuring resources for programs and surveillance.
How Best to Managed a Pandemic| Crisis Management| December 22, 2020paul young cpa, cga
This document provides an overview and updates on the global race to develop vaccines and testing for COVID-19. It profiles over a dozen pharmaceutical companies and research organizations working on vaccine development, including CanSino, Novavax, CureVac, and Moderna. It also discusses the development of testing kits and options for treating COVID-19 such as antibodies and public health interventions. The document analyzes financing, clinical trials, production challenges and geopolitical factors shaping the pandemic response.
Global Vaccines Market 2020 By Technology [Conjugate vaccines, Inactivated and subunit vaccines, Live attenuated vaccines, Recombinant vaccines, Toxoid vaccines and others],By Type [Monovalent vaccines, Multivalent vaccines and others], By Patient Type[Pediatric patients, Adult patients and others], By Disease[Cancer, Dengue, DTP, Hepatitis, Human Papilloma Virus, Influenza, Meningococcal Disease, Pneumococcal disease, Polio, Rotavirus and others]: Global Forecast to 2026 and COVID-19 Impact Outlook
Global Vaccines Market is valued at USD 45.9 Billion in 2019 and expected to reach USD 91.9 Billion by 2026 with the CAGR of 10.44 % over the forecast period.
Research Dive has recently added a new report on Human Papillomavirus Vaccine Market Size Share which provides a succinct analysis of the market size, revenue forecast, and the regional landscape of Human Papillomavirus Vaccine Market Size Share
This document provides a summary of key developments from the Gavi CEO Board Update meeting on June 24-25, 2020. It discusses the global impact of the COVID-19 pandemic, the success of Gavi's replenishment and vaccine summit, Gavi's role in the COVID-19 response including efforts to ensure equitable access to vaccines, and priorities around demand generation, communities, gender and digital engagement. It also provides updates on Gavi's 2019 progress and the conclusion of the pneumococcal AMC pilot.
GLOBAL VACCINATION: HOW THE EVOLVING HEALTHCARE INFRASTRUCTURE IS SUPPORTING ...Anayasharma10
COVID-19 (coronavirus) vaccines have started becoming accessible in most countries and are probably a severe product in fighting the pandemic in 2021. Several vaccines are already in the development trails or phase three trials that have reported promising data in the initial phase, with some receiving authorization for use.
The document provides an overview of the current Canadian vaccine environment, including:
1) The global and Canadian vaccine markets, which are growing significantly but still represent a small portion of pharmaceutical markets.
2) The complex process required for introducing new vaccines, which involves regulatory approval, funding, recommendations, and infrastructure.
3) The key players in Canada's vaccine system, including manufacturers, government agencies, medical societies, and others.
4) Recommendations to improve Canada's vaccine system by recognizing its value, encouraging investment, streamlining processes, and ensuring resources for programs and surveillance.
How Best to Managed a Pandemic| Crisis Management| December 22, 2020paul young cpa, cga
This document provides an overview and updates on the global race to develop vaccines and testing for COVID-19. It profiles over a dozen pharmaceutical companies and research organizations working on vaccine development, including CanSino, Novavax, CureVac, and Moderna. It also discusses the development of testing kits and options for treating COVID-19 such as antibodies and public health interventions. The document analyzes financing, clinical trials, production challenges and geopolitical factors shaping the pandemic response.
Paul Young provides a summary of the global race to develop COVID-19 vaccines and testing. He profiles 13 companies working on vaccines, including CanSino, Symvivo, Novavax, CureVac, and Medicago. These companies are at different stages, with some already in clinical trials. Funding is coming from various sources including governments, coalitions, and private investors. The document also discusses testing kits, treatments, and the roles of various organizations in addressing the pandemic.
This document provides an overview and updates on the global race to develop vaccines and treatments for COVID-19. It profiles over a dozen companies and organizations working on vaccine development, including CanSino, Novavax, CureVac, and Moderna. The document also discusses testing efforts and options for treatment, such as antibodies and mitigation strategies. Major players like the WHO, CDC, and governments are monitoring the situation and impacts on healthcare systems, economies, and case/death counts.
Paul Young provides a summary of the global race to develop COVID-19 vaccines and testing. He profiles several key companies involved including CanSino Biologics, Symvivo Corporation, Novovax, CureVac, Generex, Vaxart, and Medicago. Many of these companies have received funding from governments and organizations like the Bill & Melinda Gates Foundation to accelerate vaccine development. The document also discusses testing kits, treatments, and the efforts of government and health organizations in monitoring the pandemic.
How to best manage a Pandemic| Crisis Management| December 20,2020paul young cpa, cga
Dosage
Although high income countries are currently buying the larger shares of doses, India has ordered 1.5 billion—more than any other individual country.
The U.S., in comparison, has pre-purchased 1.01 billion doses, and although this number is less than the amount India has purchased, the U.S. has around 330 million people compared to India’s burgeoning 1.3 billion citizens.
Source - https://www.visualcapitalist.com/tracking-covid-19-vaccines-around-the-world/
Despite this public commitment to equity, individual countries are incentivized to purchase as many vaccine doses (and from as wide a pool of candidates) as possible to increase their chances of covering their population. Before any vaccine candidates are even approved for market, confirmed purchases cover 7.7 billion doses, with another 3.9 billion doses currently under negotiation or reserved as optional expansions of existing deals.
Source - https://launchandscalefaster.org/COVID-19
Vaccine Tracker
Other countries have gotten a head start on vaccinations. China and Russia authorized their own shots in July and August before they had been fully tested. Since then, they have vaccinated hundreds of thousands of people.
UK and United States have received early supply of vaccines.
Source - https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/
Un who global vaccine market features and trendsPublicLeaks
The document discusses trends in the global vaccine market. It notes that the market has tripled in value since 2000 due to factors like new vaccines and demand from developing countries. While most population and disease burden is in developing countries, they account for a small share of market value. New players have entered the market and consolidation among manufacturers has occurred. Emerging manufacturers now account for nearly half of pre-qualified vaccines. The UN market, through agencies like UNICEF and PAHO, has grown rapidly and accounts for over 7% of vaccine sales. The trends point to a rapidly growing yet complex market with both opportunities and challenges in ensuring access to vaccines.
How best to Management a Pandemic| Geopolitical Event| November 25, 2020 paul young cpa, cga
This document provides an overview and update on the global race to develop vaccines and testing for COVID-19. It profiles over a dozen companies and organizations working on vaccines or testing, including CanSino, Novavax, CureVac, Medicago, and Altimmune. The document also discusses treatment options like antibodies and convalescent plasma. Testing kits can cost around $129 per person and the global testing market is projected to reach $44 billion in 2020. While vaccines are progressing in trials, antibodies from prior infection may only provide short-term immunity. Continued preventative measures are still encouraged.
A recent report from Renub Research, titled "Global Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2028," offers a thorough analysis of the industry and market share knowledge. The report also includes research on regions, competitors, and the recent expansion of the Global Vaccine Market.
Israel still leads the world in terms of vaccinations - https://ourworldindata.org/covid-vaccinations
There have been issues with PCR testing - https://theorca.ca/visiting-pod/failure-to-use-rapid-tests-points-to-deeper-problems/ or All testing needs to be done in relations with other tests - https://www.politifact.com/factchecks/2021/jan/22/gateway-pundit/who-did-not-admit-pcr-tests-grossly-inflate-positi/
Global economy will have a long road to recovery - https://www2.deloitte.com/us/en/insights/economy/global-economic-outlook/weekly-update.html/
Global Risks - https://www.youtube.com/watch?v=83rTDoqdCtY
Poverty - https://www.thehindu.com/news/international/oxfam-urges-radical-economic-rejig-for-post-covid-world/article33655102.ece
Progress on COVID-19 Vaccine DevelopmentAnil Sigdel
The document discusses progress on COVID-19 vaccine development. It outlines the typical vaccine development process, including exploratory, pre-clinical, clinical trial, and regulatory approval stages. For COVID-19 vaccines, 28 candidates are currently in clinical trials, with 6 in Phase III. Two vaccines have received limited or early approval - one by China and one by Russia, though the WHO has not yet approved any vaccine. It may still take 12-18 months to develop an approved vaccine. Continued preventative measures are still needed while vaccine development progresses.
Management of a Pandemic| COVID-19| Analysis and Commentarypaul young cpa, cga
This document provides an overview and update on the global race to develop vaccines and testing for COVID-19. It discusses several major pharmaceutical companies and research organizations working on vaccine development, including CanSino, Novavax, CureVac, and Altimmune. It also covers companies involved in testing, such as Quest Diagnostics, and potential treatments using antibodies or genome sequencing. Global funding from organizations like the Gates Foundation and governments is supporting many of these efforts.
This document provides an overview and updates on the global race to develop vaccines and testing for COVID-19. It profiles several key companies involved in vaccine development, including CanSino Biologics, Symvivo Corporation, Novavax, CureVac, Generex, Vaxart, Medicago, and Altimmune. It also discusses companies involved in testing, treatment options like antibodies, and global testing market trends. Major funding sources like the Bill and Melinda Gates Foundation and governments are supporting many of these efforts. Additional research is still needed but progress is being made on vaccines, testing, and treatments.
Paul Young presented information on the global race to develop a COVID-19 vaccine and testing. Several companies were highlighted including CanSino, Symvivo, Novavax, CureVac, Generex, and Vaxart that are developing vaccine candidates using various technologies. Updates were provided on vaccine development by companies like GSK, Moderna, and partnerships involving the Gates Foundation. Information was also presented on testing including new rapid tests in development and the high costs associated with global testing.
- Many pharmaceutical companies and research institutions are racing to develop a COVID-19 vaccine. Key players discussed include CanSino, Novavax, CureVac, and Moderna.
- Testing is also a major focus. Rapid at-home testing kits that provide results within 10 minutes are in development. The global COVID testing market is expected to reach $44 billion in 2020.
- Potential treatment options discussed include convalescent plasma from recovered patients and further research on antibodies and the human genome to better understand risk factors and immunity. However, antibody levels appear to decrease significantly within 2-3 months.
Can Canadian Vaccine Research Survive the Challenges of Globalization?pcirnkt
1) Globalization of the vaccine industry has led major vaccine companies to conduct fewer clinical trials in Canada, threatening the stability of academic vaccine research centers.
2) A network of experienced vaccine trial centers in Canada could help attract more industry-sponsored studies and demonstrate value through world-class immunology research.
3) Program evaluation and research on vaccine effectiveness, safety, and value is increasingly important but underfunded in Canada; greater investment could distinguish Canada's research and improve immunization programs.
Unicef o'connell equity and vaccine supply 5_sep13Rosella Anstine
The document discusses UNICEF's work on vaccines and equity. It notes that while progress has been made on child mortality goals, inequities remain across regions, populations, and causes of death. UNICEF aims to accelerate progress and sustain momentum post-2015 through more strategic, targeted interventions. Data insights and innovations allow identifying high-risk districts and populations. UNICEF's role in vaccine procurement for over 100 countries is described, noting increasing demand due to new vaccines. Challenges include fragile supply chains and competing priorities. Maintaining stable, affordable vaccine supply requires diversified suppliers and forecasting aligned with programs. Planning must begin early for new vaccines like typhoid to ensure equitable introduction and measurement of coverage.
The Future Landscape of Covid-19 Vaccine MarketMehdiMehdiyev4
We believe that assessing the potential market for COVID-
19 vaccines is necessary in terms of reevaluating the risk/reward ratio of certain vaccine developing companies.
In addition, an overly utopian outlook for a potential COVID-19 vaccine market may lead to
disappointment and negatively affect future vaccine developers. And this concerns us more.
- Many pharmaceutical companies and research institutions around the world are racing to develop a vaccine for COVID-19. Some of the leading candidates include vaccines in development by CanSino, Novavax, CureVac, and Moderna.
- Testing is also ramping up globally to identify cases and track the spread of the virus. Rapid at-home test kits that provide results within 10 minutes are in development.
- Treatments under investigation include convalescent plasma from recovered patients, as antibodies may provide some protection. However, research shows antibody levels start declining within 2-3 months.
Management of a Pandemic| COVID-19| Canada and the World paul young cpa, cga
The document provides an overview and update on the global race to develop a COVID-19 vaccine. It discusses several key pharmaceutical companies and research organizations involved in vaccine development efforts, including CanSino, Symvivo, Novavax, CureVac, Generex, and Vaxart. It also covers testing approaches and kits, treatment options like antibodies and genome research, as well as global markets and funding sources like the Bill and Melinda Gates Foundation.
This document provides guidance for building confidence in COVID-19 vaccines among healthcare personnel and patients. It discusses the COVID-19 vaccines that are expected to receive emergency authorization, how they were tested and monitored for safety, and strategies for mitigating side effects like fever and soreness that may cause absenteeism. It also outlines elements of vaccine confidence like safety, effectiveness, and ease of access. Recommended strategies to increase confidence include engaging leaders to promote vaccines, addressing common concerns, and emphasizing the role of healthcare workers in ending the pandemic.
Ionblox has developed high-performance lithium-ion battery cells using a proprietary pre-lithiated silicon-based anode that can deliver up to 400 Wh/kg. Their cells have been validated by US National Labs and Lilium, a leading eVTOL company. Ionblox has received $32M in funding to commercialize their technology. Their silicon anode solves issues like swelling through pre-lithiation and can provide fast charging, high energy, power and long cycle life simultaneously. Ionblox's cells are the only ones that can meet the demanding requirements for electric aerial vehicles and vehicles in general.
CONCEPT OF OPERATIONS: THE TRANSITION FROM CREWED TO UNCREWED UAMiQHub
The document outlines a concept of operations for uncrewed urban air mobility (UAM). It describes key stakeholders in UAM including the flying public, regulatory agencies, and UAM industry players. The concept involves enabling infrastructure like vertiports and airspace, as well as UAM aircraft and command and control links. A steppingstone approach is proposed that evolves from current piloted UAM to eventually fully autonomous multi-vehicle operations managed remotely. Key roles and responsibilities are defined for entities involved in UAM operations. The passenger journey and nominal flight operations are illustrated from pre-flight planning through post-flight activities.
More Related Content
Similar to LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE
Paul Young provides a summary of the global race to develop COVID-19 vaccines and testing. He profiles 13 companies working on vaccines, including CanSino, Symvivo, Novavax, CureVac, and Medicago. These companies are at different stages, with some already in clinical trials. Funding is coming from various sources including governments, coalitions, and private investors. The document also discusses testing kits, treatments, and the roles of various organizations in addressing the pandemic.
This document provides an overview and updates on the global race to develop vaccines and treatments for COVID-19. It profiles over a dozen companies and organizations working on vaccine development, including CanSino, Novavax, CureVac, and Moderna. The document also discusses testing efforts and options for treatment, such as antibodies and mitigation strategies. Major players like the WHO, CDC, and governments are monitoring the situation and impacts on healthcare systems, economies, and case/death counts.
Paul Young provides a summary of the global race to develop COVID-19 vaccines and testing. He profiles several key companies involved including CanSino Biologics, Symvivo Corporation, Novovax, CureVac, Generex, Vaxart, and Medicago. Many of these companies have received funding from governments and organizations like the Bill & Melinda Gates Foundation to accelerate vaccine development. The document also discusses testing kits, treatments, and the efforts of government and health organizations in monitoring the pandemic.
How to best manage a Pandemic| Crisis Management| December 20,2020paul young cpa, cga
Dosage
Although high income countries are currently buying the larger shares of doses, India has ordered 1.5 billion—more than any other individual country.
The U.S., in comparison, has pre-purchased 1.01 billion doses, and although this number is less than the amount India has purchased, the U.S. has around 330 million people compared to India’s burgeoning 1.3 billion citizens.
Source - https://www.visualcapitalist.com/tracking-covid-19-vaccines-around-the-world/
Despite this public commitment to equity, individual countries are incentivized to purchase as many vaccine doses (and from as wide a pool of candidates) as possible to increase their chances of covering their population. Before any vaccine candidates are even approved for market, confirmed purchases cover 7.7 billion doses, with another 3.9 billion doses currently under negotiation or reserved as optional expansions of existing deals.
Source - https://launchandscalefaster.org/COVID-19
Vaccine Tracker
Other countries have gotten a head start on vaccinations. China and Russia authorized their own shots in July and August before they had been fully tested. Since then, they have vaccinated hundreds of thousands of people.
UK and United States have received early supply of vaccines.
Source - https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/
Un who global vaccine market features and trendsPublicLeaks
The document discusses trends in the global vaccine market. It notes that the market has tripled in value since 2000 due to factors like new vaccines and demand from developing countries. While most population and disease burden is in developing countries, they account for a small share of market value. New players have entered the market and consolidation among manufacturers has occurred. Emerging manufacturers now account for nearly half of pre-qualified vaccines. The UN market, through agencies like UNICEF and PAHO, has grown rapidly and accounts for over 7% of vaccine sales. The trends point to a rapidly growing yet complex market with both opportunities and challenges in ensuring access to vaccines.
How best to Management a Pandemic| Geopolitical Event| November 25, 2020 paul young cpa, cga
This document provides an overview and update on the global race to develop vaccines and testing for COVID-19. It profiles over a dozen companies and organizations working on vaccines or testing, including CanSino, Novavax, CureVac, Medicago, and Altimmune. The document also discusses treatment options like antibodies and convalescent plasma. Testing kits can cost around $129 per person and the global testing market is projected to reach $44 billion in 2020. While vaccines are progressing in trials, antibodies from prior infection may only provide short-term immunity. Continued preventative measures are still encouraged.
A recent report from Renub Research, titled "Global Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2028," offers a thorough analysis of the industry and market share knowledge. The report also includes research on regions, competitors, and the recent expansion of the Global Vaccine Market.
Israel still leads the world in terms of vaccinations - https://ourworldindata.org/covid-vaccinations
There have been issues with PCR testing - https://theorca.ca/visiting-pod/failure-to-use-rapid-tests-points-to-deeper-problems/ or All testing needs to be done in relations with other tests - https://www.politifact.com/factchecks/2021/jan/22/gateway-pundit/who-did-not-admit-pcr-tests-grossly-inflate-positi/
Global economy will have a long road to recovery - https://www2.deloitte.com/us/en/insights/economy/global-economic-outlook/weekly-update.html/
Global Risks - https://www.youtube.com/watch?v=83rTDoqdCtY
Poverty - https://www.thehindu.com/news/international/oxfam-urges-radical-economic-rejig-for-post-covid-world/article33655102.ece
Progress on COVID-19 Vaccine DevelopmentAnil Sigdel
The document discusses progress on COVID-19 vaccine development. It outlines the typical vaccine development process, including exploratory, pre-clinical, clinical trial, and regulatory approval stages. For COVID-19 vaccines, 28 candidates are currently in clinical trials, with 6 in Phase III. Two vaccines have received limited or early approval - one by China and one by Russia, though the WHO has not yet approved any vaccine. It may still take 12-18 months to develop an approved vaccine. Continued preventative measures are still needed while vaccine development progresses.
Management of a Pandemic| COVID-19| Analysis and Commentarypaul young cpa, cga
This document provides an overview and update on the global race to develop vaccines and testing for COVID-19. It discusses several major pharmaceutical companies and research organizations working on vaccine development, including CanSino, Novavax, CureVac, and Altimmune. It also covers companies involved in testing, such as Quest Diagnostics, and potential treatments using antibodies or genome sequencing. Global funding from organizations like the Gates Foundation and governments is supporting many of these efforts.
This document provides an overview and updates on the global race to develop vaccines and testing for COVID-19. It profiles several key companies involved in vaccine development, including CanSino Biologics, Symvivo Corporation, Novavax, CureVac, Generex, Vaxart, Medicago, and Altimmune. It also discusses companies involved in testing, treatment options like antibodies, and global testing market trends. Major funding sources like the Bill and Melinda Gates Foundation and governments are supporting many of these efforts. Additional research is still needed but progress is being made on vaccines, testing, and treatments.
Paul Young presented information on the global race to develop a COVID-19 vaccine and testing. Several companies were highlighted including CanSino, Symvivo, Novavax, CureVac, Generex, and Vaxart that are developing vaccine candidates using various technologies. Updates were provided on vaccine development by companies like GSK, Moderna, and partnerships involving the Gates Foundation. Information was also presented on testing including new rapid tests in development and the high costs associated with global testing.
- Many pharmaceutical companies and research institutions are racing to develop a COVID-19 vaccine. Key players discussed include CanSino, Novavax, CureVac, and Moderna.
- Testing is also a major focus. Rapid at-home testing kits that provide results within 10 minutes are in development. The global COVID testing market is expected to reach $44 billion in 2020.
- Potential treatment options discussed include convalescent plasma from recovered patients and further research on antibodies and the human genome to better understand risk factors and immunity. However, antibody levels appear to decrease significantly within 2-3 months.
Can Canadian Vaccine Research Survive the Challenges of Globalization?pcirnkt
1) Globalization of the vaccine industry has led major vaccine companies to conduct fewer clinical trials in Canada, threatening the stability of academic vaccine research centers.
2) A network of experienced vaccine trial centers in Canada could help attract more industry-sponsored studies and demonstrate value through world-class immunology research.
3) Program evaluation and research on vaccine effectiveness, safety, and value is increasingly important but underfunded in Canada; greater investment could distinguish Canada's research and improve immunization programs.
Unicef o'connell equity and vaccine supply 5_sep13Rosella Anstine
The document discusses UNICEF's work on vaccines and equity. It notes that while progress has been made on child mortality goals, inequities remain across regions, populations, and causes of death. UNICEF aims to accelerate progress and sustain momentum post-2015 through more strategic, targeted interventions. Data insights and innovations allow identifying high-risk districts and populations. UNICEF's role in vaccine procurement for over 100 countries is described, noting increasing demand due to new vaccines. Challenges include fragile supply chains and competing priorities. Maintaining stable, affordable vaccine supply requires diversified suppliers and forecasting aligned with programs. Planning must begin early for new vaccines like typhoid to ensure equitable introduction and measurement of coverage.
The Future Landscape of Covid-19 Vaccine MarketMehdiMehdiyev4
We believe that assessing the potential market for COVID-
19 vaccines is necessary in terms of reevaluating the risk/reward ratio of certain vaccine developing companies.
In addition, an overly utopian outlook for a potential COVID-19 vaccine market may lead to
disappointment and negatively affect future vaccine developers. And this concerns us more.
- Many pharmaceutical companies and research institutions around the world are racing to develop a vaccine for COVID-19. Some of the leading candidates include vaccines in development by CanSino, Novavax, CureVac, and Moderna.
- Testing is also ramping up globally to identify cases and track the spread of the virus. Rapid at-home test kits that provide results within 10 minutes are in development.
- Treatments under investigation include convalescent plasma from recovered patients, as antibodies may provide some protection. However, research shows antibody levels start declining within 2-3 months.
Management of a Pandemic| COVID-19| Canada and the World paul young cpa, cga
The document provides an overview and update on the global race to develop a COVID-19 vaccine. It discusses several key pharmaceutical companies and research organizations involved in vaccine development efforts, including CanSino, Symvivo, Novavax, CureVac, Generex, and Vaxart. It also covers testing approaches and kits, treatment options like antibodies and genome research, as well as global markets and funding sources like the Bill and Melinda Gates Foundation.
This document provides guidance for building confidence in COVID-19 vaccines among healthcare personnel and patients. It discusses the COVID-19 vaccines that are expected to receive emergency authorization, how they were tested and monitored for safety, and strategies for mitigating side effects like fever and soreness that may cause absenteeism. It also outlines elements of vaccine confidence like safety, effectiveness, and ease of access. Recommended strategies to increase confidence include engaging leaders to promote vaccines, addressing common concerns, and emphasizing the role of healthcare workers in ending the pandemic.
Similar to LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE (20)
Ionblox has developed high-performance lithium-ion battery cells using a proprietary pre-lithiated silicon-based anode that can deliver up to 400 Wh/kg. Their cells have been validated by US National Labs and Lilium, a leading eVTOL company. Ionblox has received $32M in funding to commercialize their technology. Their silicon anode solves issues like swelling through pre-lithiation and can provide fast charging, high energy, power and long cycle life simultaneously. Ionblox's cells are the only ones that can meet the demanding requirements for electric aerial vehicles and vehicles in general.
CONCEPT OF OPERATIONS: THE TRANSITION FROM CREWED TO UNCREWED UAMiQHub
The document outlines a concept of operations for uncrewed urban air mobility (UAM). It describes key stakeholders in UAM including the flying public, regulatory agencies, and UAM industry players. The concept involves enabling infrastructure like vertiports and airspace, as well as UAM aircraft and command and control links. A steppingstone approach is proposed that evolves from current piloted UAM to eventually fully autonomous multi-vehicle operations managed remotely. Key roles and responsibilities are defined for entities involved in UAM operations. The passenger journey and nominal flight operations are illustrated from pre-flight planning through post-flight activities.
INNOVATIVE SOLUTIONS FOR HIGH-POWER-DENSITY E-MOTORS FOR AEROSPACE PROPULSIONiQHub
Ansys provides comprehensive simulation solutions for electric motor development from concept design to detailed analysis and verification. Their suite includes Motor-CAD for multiphysics concept design, Maxwell for electromagnetic analysis, Fluent for thermal analysis, and Twin Builder for system simulation using reduced order models. These tools allow for optimization and mitigation of challenges like high power density, efficiency, EMI, and thermal management.
AN ELECTRIC FUTURE - READYING AIRPORTS FOR ELECTRIC AIRCRAFTiQHub
The document discusses planning considerations for electric aircraft and infrastructure at airports, including new electric aircraft types and roles, options for charging infrastructure both on and off airport, requirements for integrating electric aircraft into airfield and landside planning while addressing environmental impacts, and guidance from the FAA on reviewing proposed electric aircraft facilities and infrastructure. It also covers energy demand considerations, potential sources of electricity, and financial planning options including FAA grant programs to support development of infrastructure for electric aircraft.
ELECTRIFICATION OF AVIATION: HYPE OR GAME-CHANGER?iQHub
The document discusses advanced air mobility and whether it represents hype or a game changer. It notes that the industry experienced strong growth and funding from 2012 to 2021 but has since seen valuations plummet and funding decline sharply. This represents a typical hype cycle as the industry now separates promising projects from those that are less viable. For advanced air mobility to truly succeed, more funding is needed to focus on certification and overcoming technical challenges, while ensuring sustainability, customer experience, and use cases that can significantly reduce airline emissions like regional air mobility. Visionaries who can advance their technologies during this challenging period have the potential to emerge successfully on the other side.
HYBRIDIZATION IS THE MISSING LINK BETWEEN ELECTRIFICATION AND SUSTAINABLE FUELSiQHub
1) Electric motors are changing aircraft design in the same way jet engines did in the mid-20th century, opening possibilities like distributed electric propulsion.
2) While batteries are well-suited for delivering power, sustainable fuels have advantages for storing energy and are a more practical near-term solution compared to batteries.
3) Hybrid electric systems that combine sustainable fuels with batteries can provide emissions reductions while leveraging new aircraft design options enabled by electric motors.
LAUNCHING UAM SERVICES IN A LARGE CITY: THE ROME EXPERIENCEiQHub
Urban aircraft are seen as a solution to growing traffic congestion issues. UrbanV is a company established to operate vertiport networks globally to enable aerial mobility. UrbanV plans to launch commercial operations in Rome by the end of 2024, being one of the first cities worldwide. They are developing vertiport networks in Rome, Venice, French Riviera, and Bologna. UrbanV has already built a test vertiport in Rome where they conduct tests with industry partners.
ADVANCED BIO-CIRCULAR MATERIALS: HIGH-PERFORMANCE AND DURABLE PRODUCTSiQHub
This document summarizes an advanced materials conference that discussed Arkema's sustainable biobased and circular polyamide 11 materials. The summary is:
1) Arkema produces polyamide 11 from castor oil which is derived from castor beans grown through sustainable farming practices.
2) Their polyamide 11 has various advanced properties and is used in applications like electronics, automotive, and medical devices.
3) Arkema is committed to sustainability and circularity, with initiatives to increase renewable energy usage, improve farming practices, and develop recycling programs.
HOW TO CREATE A NET ZERO PLASTIC SOCIETY FROM THE CONVERTORS POINT OF VIEW?iQHub
Ternova Group aims to become Latin America's most sustainable company by 2040. It has taken steps such as becoming carbon neutral in 2018 and pledging to be plastic neutral. The company redesigned itself, products, and value chain to increase recycled content in products up to 95% and transition to a circular economy model for plastics. It works with partners across 39 countries and 4 continents to increase recycling globally.
BIO-BASED ADDITIVES TO IMPROVE THE PERFORMANCE & PROCESSING OF BIOPOLYMERSiQHub
This document summarizes Cargill's bio-based additives for improving the performance and processing of biopolymers. It introduces various additive types including slip, anti-block, anti-scratch, and anti-static additives. Specific additive product examples are provided along with data on their effects. Test results show additives can improve properties like coefficient of friction, scratch resistance, and charge decay rate while maintaining clarity and mechanical properties of polymers. Food-contact approvals and renewable content information is also presented.
CLOSING THE LOOP ON MATERIALS COLLECTED AND SORTING: CURBSIDE COLLECTIONiQHub
The document discusses Titus MRF Services, a company that provides solutions for improving material recovery and recycling. It summarizes Titus' projects including glass cleaning systems, film recycling, and MRF installations. It then discusses Titus' role in developing secondary MRFs that can further sort residuals from primary MRFs to recover more materials like mixed plastics. Implementing secondary MRFs across major metro areas could increase diversion rates and reduce environmental impacts.
ARE "NATURAL" POLYMERS PLANT-DERIVED POLYMERS? - CONSUMERS PERSPECTIVESiQHub
The document discusses a study on perceptions of sustainable plastics. It introduces 6 sample cups made of different polymers and tests how people rank them based on sustainability attributes. Key findings are that cups perceived as plant-derived, like those made of sugar-HDPE or cellulose/PP composite, are seen as more sustainable. However, durability is also valued, so petroleum-based cups like copolyester and PLA rank higher on durability. Disclosing a plant source makes polymers seem more sustainable to consumers.
BIO-BASED ENGINEERING PLASTICS WITH SUSTAINABILITY, HIGH FUNCTIONALITY, AND ...iQHub
The document summarizes Mitsubishi Chemical's bio-based engineering plastic DURABIO. DURABIO is a polycarbonate copolymer made mainly from plant sugars that offers high functionality, sustainability and transparency. It combines advantages of polycarbonate and PMMA, including impact strength, heat resistance, transparency and weather resistance. DURABIO can be mass produced using existing polycarbonate plants and offers properties suitable for automotive interior/exterior parts, electronics housings and outdoor walls without needing painting. Its use supports circular economy goals through potential for recycling and its bio-based renewable raw materials.
STAGES OF SUSTAINABILITY: TRANSITION FROM BROAD TERMINOLOGY TO MARKET UNDERS...iQHub
Companies that engage in greenwashing typically exaggerate environmental claims or benefits to mislead consumers into thinking products are more environmentally friendly than they actually are. They make unsubstantiated claims about environmental safety or benefits to capitalize on growing demand for green products while conveying a false impression of environmental soundness. Greenwashing was coined in 1986 to describe this deceptive marketing practice.
MAKING PLASTICS FULLY SUSTAINABLE, THE DECARBONIZED PLASTICS-TO-HYDROGEN PATHWAYiQHub
This document discusses making plastics production more sustainable through a decarbonized plastics-to-hydrogen pathway. It introduces Ways2H, a company that designs systems to convert solid organic waste like plastics, biomass, and food waste into carbon-negative hydrogen through a proprietary thermochemical process. This hydrogen can then be used as fuel for transportation and power generation. The process also integrates carbon capture and mineralization to sequester carbon dioxide. Standard systems can process 24 tons of waste per day and produce enough hydrogen to fuel 500 fuel cell vehicles daily while sequestering 57 tons of carbon dioxide. The business case shows return on investment within 2 to 5 years between carbon credits and avoided waste processing costs.
ECO-FRIENDLY AND SUSTAINABLE SOLUTIONS PROGRESSING CIRCULAR ECONOMYiQHub
Budenheim offers sustainable solutions for the life science and materials science markets, including circular economy solutions. They have expertise in polymer processing and formulation. Their products include masterbatches, flame retardants, and additives that provide benefits such as lightweighting, energy efficiency, and improved performance while reducing CO2 emissions. Their foaming agents can reduce part weight by over 10% through cellular structure formation. They also offer color masterbatches that maximize recyclate usage and enable detection and sorting of colored plastics for recycling.
SUPPORTING SUSTAINABLE PLASTICS THROUGH ADDITIVESiQHub
The document summarizes a presentation on supporting sustainable plastics through additives. It discusses challenges with recycling goals versus reality, how polymer properties deteriorate during recycling without stabilization, and case studies showing how Baerlocher's RST stabilizer blends can improve the stability and properties of post-consumer recycled resins during processing and in final products like blow molded bottles. The studies found stabilization reduced degradation, crosslinking, and variability to provide more consistent processing and strengthened final part properties.
AUTOMATED VISCOMETERS FOR MEASURING THE DIVIDING LINES AMONG RECYCLED PLASTICSiQHub
The document discusses measuring the intrinsic viscosity (IV) of polymers using an automated viscometer. It begins by explaining that IV measurements are used to characterize polymers and correlate their molecular size/weight with processing and physical properties. It then describes how the miniPV automated viscometer provides precise, efficient IV measurements compared to manual methods. The document concludes that IV is a surrogate for molecular weight and forms the basis for evaluating and comparing recycled plastics.
GLOBAL EXTENDED PRODUCERS' RESPONSIBILITY DEVELOPMENTS AND WHAT THEY MEANiQHub
Extended producer responsibility (EPR) policies are shifting responsibility for post-consumer waste upstream to producers. EPR for packaging is an accepted policy approach worldwide to address environmental impacts of packaging. Producers' organizations (PROs) play an important role in EPR systems by coordinating collection, sorting, and recycling of packaging on behalf of producers. EPR presents both opportunities and challenges for industry, such as shaping legislation and greater access to recycled materials, but also potential cost increases and compliance requirements.
UTILIZING AMI TO IDENTIFY LEAKS, IRRIGATION, AND EDUCATE CUSTOMERS ABOUT WAT...iQHub
The document discusses how an AMI (advanced metering infrastructure) system can be used by a water utility to identify leaks, inefficient irrigation, and educate customers. It provides details on the city of Santa Rosa's AMI components, how they use internal reporting of high water usage to detect leaks and notify customers, set thresholds for identifying leaks and irrigation issues, and efforts to engage customers through a portal, education, and incentives. AMI has also provided benefits during emergencies like drought, COVID, and wildfires.
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...Aleksey Savkin
The Strategy Implementation System offers a structured approach to translating stakeholder needs into actionable strategies using high-level and low-level scorecards. It involves stakeholder analysis, strategy decomposition, adoption of strategic frameworks like Balanced Scorecard or OKR, and alignment of goals, initiatives, and KPIs.
Key Components:
- Stakeholder Analysis
- Strategy Decomposition
- Adoption of Business Frameworks
- Goal Setting
- Initiatives and Action Plans
- KPIs and Performance Metrics
- Learning and Adaptation
- Alignment and Cascading of Scorecards
Benefits:
- Systematic strategy formulation and execution.
- Framework flexibility and automation.
- Enhanced alignment and strategic focus across the organization.
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
Industrial Tech SW: Category Renewal and CreationChristian Dahlen
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
Easily Verify Compliance and Security with Binance KYCAny kyc Account
Use our simple KYC verification guide to make sure your Binance account is safe and compliant. Discover the fundamentals, appreciate the significance of KYC, and trade on one of the biggest cryptocurrency exchanges with confidence.
The APCO Geopolitical Radar - Q3 2024 The Global Operating Environment for Bu...APCO
The Radar reflects input from APCO’s teams located around the world. It distils a host of interconnected events and trends into insights to inform operational and strategic decisions. Issues covered in this edition include:
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...my Pandit
Dive into the steadfast world of the Taurus Zodiac Sign. Discover the grounded, stable, and logical nature of Taurus individuals, and explore their key personality traits, important dates, and horoscope insights. Learn how the determination and patience of the Taurus sign make them the rock-steady achievers and anchors of the zodiac.
4. Global Vaccine Market and Trends.…Before COVID-19 Pandemic
Significant breakthroughs in bioprocess and analytical
technologies for supporting vaccine development in 2000s
Bioprocess industry remains challenging and complex
Global vaccine market is growing rapidly, attracting interest and
new players
From 2000 to 2013, the vaccine market grew from 4 billion US
dollars to 24 billion USD
By 2028, the value of the vaccine market is estimated to be
around 100 billion USD
And more than 120 new products are in development, 60 of
which are of special importance for developing countries
Vaccine development is costly and lengthy in terms of processes
D’Amore & Yang (2019). Advances and Challenges in Vaccine Development and Manufacture. Available at: https://bioprocessintl.com/manufacturing/vaccines/advances-
and-challenges-in-vaccine-development-and-manufacture/ (accessed in Sep 2022)
3
5. Vaccine Product Profile
High Product
Sensitivity
• Biological products
• Significant risks of
production failures
• Quality is the OVER-
RIDING criterion
• Highly regulated
production
environment
• Dependency on well
functioning NRA
• Requiring constant
temperature control ⇔
Cold Chain from
Manufacturer to End
user
• Limited shelf life
Limited Supply
• 1- 5 suppliers per
product
• High entry cost to
manufacturers
• Diverse dynamics in
individual vaccine
markets
• New vaccines often
result in monopoly
supply
Vaccine
Production and
Market
competition
• Production of a
dose: 6 -24 Months
• Capacity Increase:
2-3 years
• New Plant: 5-7
years
• New regulatory
requirements can
cause interruptions
• New vaccines being
introduced globally,
global competition
• Initial selection has
long term impact
Requiring a specific approach to be developed for vaccine procurement
D’Amore & Yang (2019). Advances and Challenges in Vaccine Development and Manufacture. Available at: https://bioprocessintl.com/manufacturing/vaccines/advances-and-challenges-in-vaccine-development-and-
manufacture/ (accessed in Sep 2022); WHO Website (2020). Accessed in Sep 2022
4
6. Market Growth Prediction from 2007 to 2023
Growth Factors:
• Importance of communicable
diseases and new threats
• New vaccines, new
presentations, and indications
• Cost effectiveness of
immunizations
• New funding opportunities
(Gov, PPP, donors, Foundations..)
• New research techniques and
manufacturing technologies
• Increasing demand, new target
population, larger emerging
markets
• Higher prices, improved
profitability for the industry
• "Blockbuster" sales for some
innovative vaccines
WHO Website (2020)
5
7. Emerging Manufacturers are playing a Critical Role
Brazil: Bio-Manguinhos, Butantan Institute
China: Chengdu, Shanghai (SIBP), Sinovac, Shenzhen
AVP, Shenzhen Kangtai
Cuba: CIGB, Instituto Finlay
India: Panacea Biotec, Shantha Biotechnics, Bharat
Biotech, Biological E (BE), Serum Institute of India,
Indian Immuonologicals, Zydus cadila
Indonesia: Biofarma
Mexico: Birmex
Republic of Korea: Berna Green Cross (Berna), LG Life
Sciences (LG), SK Bioscience
Emerging market suppliers
• Critical to competition, supply security and
affordable prices
• Quality standards and requirements are the
same
• Emerging producers are playing a critical role in
developing countries: EPI and combo vaccines
• Now supplying about 50% procurement through
UNICEF by volume (less than 30% by value)
• Top country by value for UNICEF vaccine
procurement 2012 - India
WHO Website (2020)
6
9. 8
Developing Countries Vaccine Manufacturers Network (DCVMN)
DCVMN is a public health-driven alliance of corporate vaccine manufacturers based in developing countries – DCVMN members from India,
Indonesia, Bangladesh, Pakistan, Brazil, Argentina, China, Korea, Taiwan, Thailand, Vietnam, Russia
Its mandate to protect all people against known and emerging infectious diseases, by improving the availability of high-quality vaccines globally,
recognizing the need for international scientific, technical and economic cooperation
Since 2000, motivated by the WHO and the Gavi Alliance, aiming to improve vaccine supply to developing countries where populations were
growing rapidly, incidence of disease was high and purchasing power was low
This collaborative model improves manufacturers’ capabilities to supply
affordable vaccines globally
Hayman & Pagliusi (2020). Emerging vaccine manufacturers are innovating for the next decade. Vaccine; DCVMN. Available at:
https://www.dcvmn.org/-Vaccines- (accessed in May 2021)
10. 9
Developing Countries Vaccine Manufacturers Network (DCVMN) –
Cont’d
Major Achievements
• As of October 2019, DCVMN members produced over 70 WHO PQ vaccines types, in a variety of presentations, accounting for half of the total pre-qualified vaccines
• Contributing to the Polio-free world
• Ending cholera
• Tackling re-emerging diseases (e.g., measles)
• Track record of vaccine innovations
• Accelerating the R&D Pipeline (i.e., improve existing vaccines; prevent known and emerging infectious diseases; development of next-generation vaccines for TB, dengue, malaria
• As of Oct 2019, 24/181 (~15%) of vaccines development are novel vaccines never licensed, such as chikungunya, Zika, RSV, HIV, or second-generation vaccines against dengue and malaria
Hayman & Pagliusi. Emerging vaccine manufacturers are innovating for the next decade. Vaccine (2020); Jadhav, Gautam, Gairola. Role of vaccine manufacturers in
developing countries towards global healthcare by providing quality vaccines at affordable prices. CMI (2014)
India, China, Brazil, Russian,
Republic of Korea, and
Turkey recorded great growth
rates in 2012 vaccine sales
and are anticipated to
become larger than the
developed markets by 2020
12. And then COVID-19 hit the whole world !...
As of Sep 2022,
• > 600M Total COVID-19 Cases
• > 6M Total Deaths
• >190 countries/regions affected
Johns Hoskins University. Coronavirus resource center. Available at: https://coronavirus.jhu.edu/map.html
(accessed in Sep 2022)
11
13. 12
COVID-19 Vaccines Development and Platforms - Source of Various
Collaborations
Various vaccine platforms: mRNA, DNA, viral vector, inactivated, protein-subunit, LAV being developed by Pharmaceutical & Biotech companies,
including in emerging countries
As of Aug 2022:
• 356 vaccine candidates and 138 in a clinical setting and 34 vaccines in use (EUA/EUL vaccines)
PPPs are essential to vaccine development,
• especially in the early 1990s with the effort to create a vaccine for HIV/AIDS, Malaria, and Tuberculosis
• Gavi used a pre-licensure procurement commitment to fund the development of the Ebola vaccine
• Such forms of public sector support were dramatically expanded to fight Covid-19, including the U.S. government’s Operation Warp Speed
Its efforts were quantifiably successful leading to viable vaccines in a dramatically short timespan: 12–18 months compared to the average of 8–
15 years for previous vaccines
These past efforts offer valuable lessons for utilizing PPPs to address pandemics and contribute to existing infrastructure that can be deployed in
furtherance of global Covid-19 vaccine supply chains
COVID-19 Vaccine Tracker – LSHTM. Available at: https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/ (Accessed in Sep 2022); Krammer F et al. SARS-COV-2 Vaccines in Development.
Nature (2020); Savoy & Mendez-Leal (2021). Beyond COVAX. The importance of PPPs for COVID-19 Vaccine Delivery to Developing Countries
14. COVID-19 Clinical Trials in LMICs
Majority of COVID-19 clinical trials were conducted in upper- or high-income
countries
• How relevant are the study results for low-resource settings?
Few COVID-19 studies were first conducted in South Africa (AZ/Oxford, Janssen, J&J)
• More still needs to be done in Africa (e.g., Kenya, Uganda,…)
• Ready-now trial sites available in multiple countries across the continent
• IVI awarded by BMGF on Phase III site readiness to assess, support, and train study sites in 4
countries (i.e., Ghana, Mozambique, Nepal, Philippines)
Makoni. COVID-19 vaccine trials in Africa. Lancet (2020); Le TT et al. Evolution of the COVID-19 vaccine development landscape. nature reviews. Available at:
https://www.nature.com/articles/d41573-020-00151-8 (accessed in Sep 2021)
13
15. 14
Solidarity Trial Vaccines (STV):
• an international, multi-center, multi vaccine,
adaptive, shared placebo, event-driven, individually
randomized controlled clinical trial
• to evaluate the efficacy and safety of promising new
COVID-19 vaccines
The primary objective is to evaluate the effect of each
vaccine on reducing the rate of virologically confirmed
COVID-19 disease, regardless of the severity
The Solidarity Trial Vaccines has started recruitment in
selected sites in the Philippines, Mali, and Colombia
Key features of the trial include:
•mobile trial sites to enable reaching people in remote
areas and achieve more equitable recruitment
•interim analyses to identify better performing candidates
and to eliminate those that are performing poorly against
pre-specified statistical thresholds
•long-term follow-up to increase the rigor of results and
enable formal evaluation of efficacy vs. severe disease and
duration of efficacy
The selection of candidate vaccines for the STV involves
evaluation of pre-defined criteria, including:
•their safety and proven potential for effectiveness
•stability of the vaccine
•demonstration that they can be stored and transported easily
under normal conditions
•availability - whether they can be produced quickly for global
distribution
•the ease with which they can be given to individuals (how the
vaccines are given, the number of doses, etc)
Its Governance:
• International Steering Committee to govern the conduct of the
trial in accordance with the international trial protocol -
composed of representatives from participating country
governments who nominate two members – a representative of
the Ministry of Health (or national Medical Research Council, or
equivalent) and the national Principal Investigator.
• Executive Group of the Steering Committee composed of
independent international experts to ensure the study is being
conducted appropriately
• Global Data and Safety Monitoring Committee (DSMC) to
analyse confidential trial data to determine the safety and
efficacy of the vaccines being investigated
Solidarity Trial Vaccines
WHO (2022). Solidarity Trial Vaccines. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-of-
covid-19-vaccines# (Accessed in Sep 2022)
16. 15
Challenges in Global Access to COVID-19 Vaccines: Production, Affordability,
Allocation, and Deployment
Several COVID-19 vaccines are authorized or approved for use, with many more in
the late stages of clinical development
Yet having licensed vaccines is not enough to achieve global control of COVID-19:
they also need to be produced at scale, priced affordably, and allocated globally
The four dimensions of the global vaccination challenge are closely related, and the
development and production steps have important implications for pricing,
allocation, and public confidence
Wouters et al. (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet
17. COVID-19 Vaccine Manufacturing
CEPI believed that 4 billion of the 10 billion
doses of vaccine manufacturing capacity could
be used for COVID vaccines
Models predicted that we would not have
enough doses until 2024
Operation Warp Speed (US) manufactured
hundreds of millions of doses “at risk”, making
vaccines before proven to be safe and effective
Licensing/Contracting: Vaccine manufacturers
are licensing vaccines to other manufacturers:
Serum Institute (ChAdOx), Butantan (Sinovac),
SK bioscience (ChAdOx), Lonza (Moderna)
16
18. 17
Manufacturing Locations from EUL Vaccines
Moderna
AZ/Oxford
Pfizer/
BioNtech
Global vaccines needs are huge
Vaccine makers projection: 12B doses
in 2021
Production capacity for 2021 varies widely
among vaccines makers and platforms
Global manufacturing partnerships (i.e., bulk
manufacturing, fill & finish)
Sinopharm
(Beijing)
Janssen
(J&J)
Duke – Global Health Innovation Center. Available at: https://launchandscalefaster.org/covid-19/vaccinemanufacturing (accessed in Sep 2021)
19. 18
Manufacturing Partners Overview
Launch & Scale – Speedometer. Vaccine Manufacturing. Available at: Vaccine Manufacturing | Launch and Scale Speedometer (launchandscalefaster.org) (accessed in Sep 2022)
21. 20
IVI is an UN-chartered
international organization
dedicated to accelerating vaccine
R&D for global health
20
… we can achieve our VISION of developing countries free
of suffering from infectious disease
… is to expand our global presence and expand our collaborative
partnerships and innovative capabilities
… is to discover, develop and deliver safe, effective
and affordable vaccines to enable the world's most
vulnerable people to have full, productive lives
Together
Next step
Our mission
1
22. 21
Global Vaccine Research Institute
IVI is a truly
international
organization that
has work across
multiple regions
OECD–recognized International Organization
(not for profit)
HQ and labs at Seoul
National University
Field programs in
28+countries:
Asia, Africa, Latin
America
25nationalities in
workforce of 214
UNDP initiative First international
organization in Korea (1997) 39countries and WHO as
state parties (Colombia
Madagascar and Argentina
pending final submission to UN)
1
21
23. 22
IVI has built a strong network across Africa, Asia, and Latin America
that continues to grow across development and epidemiology work
in
20+
projects
28+
sites
Typhoid Cholera
Other (AMR, COVID-19,
Chikungunya, etc…)
~1000
jobs
creating
22
24. 23
IVI Vaccines Bring Affordable Innovation to Global Health
VACCINE #1
ORAL
CHOLERA
VACCINE SHANCHOL PQ 2011 EUVICHOL, EUVICHOL
PLUS PQ 2016, 2018
VACCINE #2
Vi-DT TCV
(Typhoid)
Approved by
KMFDS, WHO
submitted
BLA submitted to
BPOM
VACCINE #3
•Non-typhoidal
Salmonella
•Shigella
COST
VACCINE MANUFACTURER
Cost thru
PQ: $28M
Estimated
Cost thru
PQ: $33M
IVI internal
investment
preclinical POC;
Wellcome Trust
$3.2M
25. 24
has enhanced Korean vaccine manufacturing capacity
2016 2021
“Vaccine 3.0”
Infrastructure building
project for vaccine self
sufficiency
2016-2020
• Funded by ROK government,
BMGF, Korean
manufacturers
• Focuses on global health
R&D
• E.g. Cholera Conjugate
Vaccine (CCV)
• Partner with Vaccine
Innovative Technology Alliance
(VITAL) Korea to promote R&D
for global health
• Promote vaccine sovereignty
of Korea and preparedness
against EID
“K-Vaccine Hub”
Center of Excellence, providing essential support
required in establishing K-Bio Hub
• Vaccine research: platform technology
(mRNA, viral vector), adjuvant
• Innovation center: vaccine evaluation system
through standard assays and reagents
• Translational hub: clinical development,
regulatory affairs, and quality assurance
• Globalization: provide networking to industry
to move to the next level
OCV, TCV, HEP B,
HEP A, MERS
Vaccine
• Euvichol® &
Euvichol-Plus® OCV
• Vi-DT TCV
• iNTS
• Hep B microneedle
patch
• Hep A • MERS
COVID-19
Vaccine1
Vaccine product
development
partnerships
with Korean
manufacturers
& agencies
2018 2020
1. Additional partners include Hanmi Pharmaceuticals, NeoImmuneTech, Bioapp, GI Cell, GI Innovation, POSVAX, GeneMatrix and Korea Mouse Phenotyping Center (KMPC)
26. 25
IVI works throughout the value chain to enable our global partners in COVID-19 vaccine
development
Pre-clinical and International Standard
Serum & Assay Development
Capacity Building
• Support for Epi. and Phase
III site development
Clinical Development
• Laboratory: EIA, PRNT, PsVNa
• Phase I-III / effectiveness
IVI is testing COVID-19 vaccines from companies that have committed
~1 billion doses of COVID-19 vaccines to COVAX (~20% of the total)
27. 26
Major Partners
IVI has 160 partners worldwide ranging from government, industry,
academia and civil society to intergovernmental organizations
New:
Denmark
28. 27
Where we'd like to be| Impact and Effectiveness
IVI has led the fight against
cholera in LMICs for 20 years with
90% of the global OCV stockpile
and developed a new-generation
typhoid conjugate vaccine
IVI is a leading PDP with a multi-country presence, bolstering existing core
capabilities such as tech transfer and disease surveillance, the launch of new
capabilities, and reformed governance to bring in 39+ country perspectives to fight
against emerging and pandemic infectious diseases by harnessing cross-cutting R&D
preparedness and capabilities through global partnerships
Path
Forward
Typhoid:
Approved by
KMFDS, WHO
submitted
Typhoid: BLA
submitted to BPOM
70 million doses
delivered and
400,000+ people
vaccinated through
IVI campaigns
Vi-DT typhoid
conjugate vaccine
pending WHO PQ
Target to
vaccinate
540,000 people
in Nepal and
Mozambique
2020-2024
30. Conclusion
Progress on vaccine development and manufacturing has been set in developing countries before the COVD-
19 pandemic, with emerging market suppliers playing a key role in developing countries (i.e., EPI and Combo
vaccines)
DCVMN is established for over 20 years with key players in vaccine development and manufacturing from
India, Indonesia, and China…
COVID-19 pandemic paradigm – Overlapping phases, shortening development time, opening-up opportunities
in vaccine development and manufacturing for developing countries, and leveraging the PPPs model would
help increase vaccine production and global supply, particularly for LMICs
The case for a coordinated multilateral response to the crisis is now well established, and further attention to
expanding access to vaccines for developing countries remains a challenge
One of the barriers to local production - biomanufacturing knowledge, intellectual property (IP) rights, and
limited technology transfer remain barriers to building additional local production capacity
Beyond PPP, IVI is committed to education and training programs and has launched the first Global Training
Hub for Biomanufacturing in July 2022, supported by the Korean Government and WHO Academy